Verona Pharma PLC (LSE:VRP) - Share price - Overview

Stock Report

Verona Pharma PLC VRP

Last Price
GBX116.50

Day Change
-1.00|-0.85%

As of 22/01/2018
11:01:06 GMT | GBX
Minimum 15 Minutes Delay.

Last Close117.50p
Day Range115.00 - 115.35
Mkt Cap123.40Mil
52-Wk Range100.00 - 165.00
Yield %0.00
ISINGB00BYW2KH80
Volume3,390
P/E-7.77
P/SInfinity
P/CF-7.09

Share Price

Total Returns 22/01/2018

 Chg (%)  
More ...
Verona Pharma PLC10.43 
FTSE 100 TR GBP1.74
 
Financials
201420152016
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-3.79-8.98-7.02
Net Profit-2.76-7.49-5.02
Reported EPS-16.00-37.00-15.00
Balance Sheet
Current Assets11.265.5743.81
Non Current Assets1.872.272.33
Total Assets13.137.8446.14
Current Liabilities0.531.8110.87
Total Liabilities0.532.4111.67
Total Equity12.615.4334.47
Cash Flow
Operating Cash Flow-3.83-7.06-7.12
Net Change in Cash9.37-6.4535.57
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-24.20-23.64--4.97---
2018-26.59-22.61--5.20---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
29/11/2017PurchaseDr. David Ebsworth106.8510,00010,685.00
17/08/2017PurchaseDr. David Ebsworth122.508,1309,959.00
27/04/2017PurchaseVikas Sinha131.37177,776233,541.00
26/04/2017PurchaseDr. David Ebsworth132.0013,37317,652.00

Company Profile

Verona Pharma PLC develops drugs for respiratory diseases. Its products mainly include anti-inflammatory agents and bronchodilators.

Sector

Biotechnology

Market Position

876 of 1835 Companies

Index

FTSE AIM All Share

Outlook

(07/11/2017) no outlook statement

Next Event 27/02/2018

Next annual report due
Ratios
CompSecMkt
More ...
PER (E)-5.2014.145.53
Div Yld (E)0.004.064.03
PEG (E)0.00-0.460.98
ROCE-18.57179.53180.33
Op Mrgn0.00-8.37-126.27
EPS Grwth0.005.7922.39
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. David Ebsworth
Chief Executive OfficerDr. Jan-Anders Karlsson
Chief Financial OfficerPiers Morgan
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.